Deutsch English Français

Contact

EP1220682

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1220682

EP1220682 - STABILIZED LIQUID POLYPEPTIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 28.09.2007 Database last updated on 03.09.2024
Most recent event Tooltip	07.08.2009	Lapse of the patent in a contracting state New state(s): CY	published on 09.09.2009 [2009/37]
Applicant(s)	For all designated states Novartis Vaccines and Diagnostics, Inc. 4560 Horton Street Emeryville, CA 94608 / US
	[2006/36]
Former [2002/28]	For all designated states CHIRON CORPORATION 4560 Horton Street Emeryville California 94608-2916 / US
Inventor(s)	01 / CHEN, Bao-Lu Intellectual Prop.-R440, P.O. Box 8097 Emeryville, CA 94622-8097 / US
	02 / HORA, Maninder Intellectual Prop.-R440, P.O. Box8 097 Emeryville, CA 94622-8097 / US
	[2002/28]
Representative(s)	Marshall, Cameron John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2005/40]	Marshall, Cameron John Carpmaels & Ransford 43-45 Bloomsbury Square London WC1A 2RA / GB
Former [2002/28]	UEXKÜLL & STOLBERG Patentanwälte Beselerstrasse 4 22607 Hamburg / DE
Application number, filing date	00968584.3	03.10.2000
	[2002/28]
	WO2000US27156
Priority number, date	US19990157696P	04.10.1999 Original published format: US 157696 P
	[2002/28]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO0124814
	Date:	12.04.2001
	Language:	EN
	[2001/15]
	Type:	A1 Application with search report
	No.:	EP1220682
	Date:	10.07.2002
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 12.04.2001 takes the place of the publication of the European patent application.
	[2002/28]
	Type:	B1 Patent specification
	No.:	EP1220682
	Date:	22.11.2006
	Language:	EN
	[2006/47]
Search report(s)	International search report - published on:	EP	12.04.2001
Classification	IPC:	A61K38/20, A61K38/57, A61K38/21, A61K47/18	[2002/28]
	CPC data not yet available
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2006/47]
Former [2002/28]	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	STABILISIERTE FLÜSSIGE PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND POLYPEPTIDE	[2002/28]
	English:	STABILIZED LIQUID POLYPEPTIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS	[2002/28]
	French:	COMPOSITIONS PHARMACEUTIQUES LIQUIDES STABILISEES CONTENANT UN POLYPEPTIDE	[2002/28]
Entry into regional phase	29.04.2002	National basic fee paid
	29.04.2002	Designation fee(s) paid
	29.04.2002	Examination fee paid
Examination procedure	03.05.2001	Request for preliminary examination filed International Preliminary Examining Authority: EP
	29.04.2002	Examination requested [2002/28]
	13.09.2002	Despatch of a communication from the examining division (Time limit: M09)
	23.06.2003	Reply to a communication from the examining division
	21.01.2004	Despatch of a communication from the examining division (Time limit: M06)
	02.08.2004	Reply to a communication from the examining division
	04.03.2005	Despatch of a communication from the examining division (Time limit: M06)
	16.08.2005	Reply to a communication from the examining division
	10.03.2006	Communication of intention to grant the patent
	18.07.2006	Fee for grant paid
	18.07.2006	Fee for publishing/printing paid
Divisional application(s)	EP04021066.8 / EP1491208
Opposition(s)	23.08.2007	No opposition filed within time limit [2007/44]
Fees paid	Renewal fee
	29.04.2002	Renewal fee patent year 03
	23.10.2003	Renewal fee patent year 04
	25.10.2004	Renewal fee patent year 05
	07.10.2005	Renewal fee patent year 06
	05.10.2006	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	22.11.2006
	CY	22.11.2006
	FI	22.11.2006
	DK	22.02.2007
	SE	22.02.2007
	GR	23.02.2007
	PT	23.04.2007
	[2009/37]
Former [2008/19]	AT	22.11.2006
	FI	22.11.2006
	DK	22.02.2007
	SE	22.02.2007
	GR	23.02.2007
	PT	23.04.2007
Former [2007/37]	AT	22.11.2006
	FI	22.11.2006
	DK	22.02.2007
	SE	22.02.2007
	PT	23.04.2007
Former [2007/36]	AT	22.11.2006
	FI	22.11.2006
	SE	22.02.2007
	PT	23.04.2007
Former [2007/28]	AT	22.11.2006
	FI	22.11.2006
	SE	22.02.2007
Former [2007/25]	FI	22.11.2006
	SE	22.02.2007
Cited in	International search	[X]EP0229016 (SHIONOGI & CO [JP], et al) [X] 1-8,16,17,20,21,24-26,32-40 * page 2, line 31 - line 39 * * page 2, line 55 - page 3, line 25 * * page 4; example 2 * * page 5 - page 6; table 1 * * claims 1-8 *;
		[X]US5078997 (HORA MANINDER S [US], et al) [X] 1-5,16,17,32-35,37,39,40 * column 2, line 17 - line 54 * * column 5, line 13 - line 17 * * column 5, line 31 - line 48 * * column 6, line 1 - line 10 * * column 6, line 30 - line 36 * * column 9 - column 10; example 3 * * column 10; example 4 * * claims 1-3,7-10,13,14 *;
		[X] - BAO-LU CHEN; XIAORONG WU; SUSAN J. BABUKA; MANNINDER HORA, "Solubility of recombinant human tissue factor pathway inhibitor", JOURNAL OF PHARMACEUTICAL SCIENCES, (1999), vol. 88, no. 9, pages 881 - 888, XP000926223 [X] 1-6,12,16-21,24,25,30,32-40 * page 883, column 1, line 17 - column 2, line 14 * * page 884, column 1, line 47 - line 61 * * page 886, column 2, line 58 - line 65 * DOI: http://dx.doi.org/10.1021/js9900708
		[X] - CHANG B S ET AL, "DEVELOPMENT OF A STABEL FREEZE-DRIED FORMULATION OF RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST", PHARMACEUTICAL RESEARCH,US,NEW YORK, NY, (19960201), vol. 13, no. 2, ISSN 0724-8741, pages 243 - 249, XP000611612 [X] 1 * page 243, column 1, line 7 - line 30 * * page 248, column 2, line 4 - line 26 * DOI: http://dx.doi.org/10.1023/A:1016043114998
	Examination	EP0303746
		EP0508194

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p